Insights

Acquisition by Sanofi Inhibrx Biosciences was acquired by Sanofi for $2.2 billion, showcasing a significant investment in the company's biologic therapeutics pipeline. This acquisition could open up new collaboration opportunities and access to Sanofi's extensive network for sales development.

Investment by Exchange Traded Concepts, LLC Exchange Traded Concepts invested $134,000 in Inhibrx Biosciences, indicating growing investor confidence in the company's potential. This investment can serve as a gateway for sales development conversations with Exchange Traded Concepts and potentially other investors in their network.

Partnership with NorthStar Medical Radioisotope Partnering with NorthStar Medical Radioisotope for the development of radiopharmaceuticals presents a new avenue for sales opportunities. This collaboration can lead to discussions on joint commercialization strategies and expanding market reach for Inhibrx's cancer treatment solutions.

Collaboration with Oxford Finance LLC By partnering with Oxford Finance LLC, Inhibrx Biosciences has strengthened its financial position, creating potential for further growth and sales expansion. This collaboration could provide opportunities for discussing financing solutions and tailored investment plans with other financial institutions.

Development of predictive biomarker with Genialis Working with Genialis to develop a predictive biomarker for solid tumors underscores Inhibrx's commitment to precision medicine. This collaboration opens doors for engaging with healthcare providers, research institutions, and pharmaceutical companies interested in advancing personalized cancer treatments.

Inhibrx Biosciences, Inc. Tech Stack

Inhibrx Biosciences, Inc. uses 8 technology products and services including Cloudflare, Font Awesome, Google Cloud, and more. Explore Inhibrx Biosciences, Inc.'s tech stack below.

  • Cloudflare
    Content Management System
  • Font Awesome
    Font Scripts
  • Google Cloud
    Infrastructure As A Service
  • AOS
    Javascript Libraries
  • Modernizr
    Javascript Libraries
  • Open Graph
    Miscellaneous
  • Microsoft
    Miscellaneous
  • Yoast SEO
    Search Engines

Media & News

Inhibrx Biosciences, Inc.'s Email Address Formats

Inhibrx Biosciences, Inc. uses at least 1 format(s):
Inhibrx Biosciences, Inc. Email FormatsExamplePercentage
First@inhibrx.comJohn@inhibrx.com
82%
FirstL@inhibrx.comJohnD@inhibrx.com
9%
Last@inhibrx.comDoe@inhibrx.com
8%
First.L@inhibrx.comJohn.D@inhibrx.com
1%

Frequently Asked Questions

Where is Inhibrx Biosciences, Inc.'s headquarters located?

Minus sign iconPlus sign icon
Inhibrx Biosciences, Inc.'s main headquarters is located at 11025 N Torrey Pines Rd Suite 140 San Diego, California 92037 US. The company has employees across 2 continents, including North AmericaEurope.

What is Inhibrx Biosciences, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact Inhibrx Biosciences, Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Inhibrx Biosciences, Inc.'s stock symbol?

Minus sign iconPlus sign icon
Inhibrx Biosciences, Inc. is a publicly traded company; the company's stock symbol is INBX.

What is Inhibrx Biosciences, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Inhibrx Biosciences, Inc.'s official website is inhibrx.com and has social profiles on LinkedIn.

How much revenue does Inhibrx Biosciences, Inc. generate?

Minus sign iconPlus sign icon
As of January 2025, Inhibrx Biosciences, Inc.'s annual revenue reached $35M.

What is Inhibrx Biosciences, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
Inhibrx Biosciences, Inc.'s SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Inhibrx Biosciences, Inc. have currently?

Minus sign iconPlus sign icon
As of January 2025, Inhibrx Biosciences, Inc. has approximately 153 employees across 2 continents, including North AmericaEurope. Key team members include Chief Financial Officer: K. D. D.Chief Scientific Officer & Evp Corporate Strategy: B. E.Vice President - Medical Affairs And Business Development: R. B.. Explore Inhibrx Biosciences, Inc.'s employee directory with LeadIQ.

What industry does Inhibrx Biosciences, Inc. belong to?

Minus sign iconPlus sign icon
Inhibrx Biosciences, Inc. operates in the Biotechnology Research industry.

What technology does Inhibrx Biosciences, Inc. use?

Minus sign iconPlus sign icon
Inhibrx Biosciences, Inc.'s tech stack includes CloudflareFont AwesomeGoogle CloudAOSModernizrOpen GraphMicrosoftYoast SEO.

What is Inhibrx Biosciences, Inc.'s email format?

Minus sign iconPlus sign icon
Inhibrx Biosciences, Inc.'s email format typically follows the pattern of . Find more Inhibrx Biosciences, Inc. email formats with LeadIQ.

How much funding has Inhibrx Biosciences, Inc. raised to date?

Minus sign iconPlus sign icon
As of January 2025, Inhibrx Biosciences, Inc. has raised $150M in funding. The last funding round occurred on Jan 13, 2025 for $150M.

When was Inhibrx Biosciences, Inc. founded?

Minus sign iconPlus sign icon
Inhibrx Biosciences, Inc. was founded in 2010.
Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc.

Biotechnology ResearchCalifornia, United States51-200 Employees

At Inhibrx, our mission is to deliver optimized, biologic therapeutics to people with life-threatening conditions. Toward this goal, we have built a large and diverse pipeline with the potential to impact cancer and orphan diseases through our single domain antibody platform technology. Single domain antibodies (sdAbs) provide a small, simple, modular target binding domain that can be combined in a variety of ways to meet specific needs of unique biological targets. Our sdAb-based therapeutic candidates have been designed to interface with the biology of each target antigen, and can be readily manufactured at high yields with established processes. We have created various multivalent and multispecific therapeutic formats that are each designed to achieve unique functions, including the ability to:

- effectively cluster receptors with precisely defined valency;
- simultaneously engage multiple antigens or epitopes;
- combine synergistic functions in a single molecule; and
- restrict therapeutic activity to the tumor microenvironment or other biologically distinct tissue.

Section iconCompany Overview

Headquarters
11025 N Torrey Pines Rd Suite 140 San Diego, California 92037 US
Phone number
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
INBX
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2010
Employees
51-200

Section iconFunding & Financials

  • $150M

    Inhibrx Biosciences, Inc. has raised a total of $150M of funding over 6 rounds. Their latest funding round was raised on Jan 13, 2025 in the amount of $150M.

  • $10M$50M

    Inhibrx Biosciences, Inc.'s revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $150M

    Inhibrx Biosciences, Inc. has raised a total of $150M of funding over 6 rounds. Their latest funding round was raised on Jan 13, 2025 in the amount of $150M.

  • $10M$50M

    Inhibrx Biosciences, Inc.'s revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.